San Diego-based Arena Pharmaceuticals has delivered positive mid-stage data on APD125, an experimental therapy for chronic insomnia. The therapy is being developed for people who have a hard time staying asleep after they go to sleep. Researchers said that the trial provided statistically significant evidence that the therapy helped those people stay asleep. A Phase III trial is slated to begin next year.
"We are very encouraged by the results from the Phase II trial, which demonstrate improved sleep maintenance with an excellent tolerability profile," said Dr. William Shanahan, Arena's Chief Medical Officer. "We look forward to the continued development of APD125, and hope to bring a safe, efficacious and non-scheduled treatment to patients to help them maintain sleep and awake refreshed."
- check out the release on the insomnia data
Related Articles:
Actelion sees positive results in new sleep trial. Report
Arena prepares pivotal trial on obesity drug. Report
Arena reports successful lorcaserin trial. Report